Literature DB >> 9884316

Detection of a novel cytochrome P-450 1A2 polymorphism (F21L) in Chinese.

J D Huang1, W C Guo, M D Lai, Y L Guo, G H Lambert.   

Abstract

Despite a wide interindividual variation of cytochrome P-450 1A2 (CYP1A2) activity, genetic polymorphism of CYP1A2 has not been reported. By amplification of exons of CYP1A2 by polymerase chain reaction in eight Chinese subjects, the polymerase chain reaction products were directly sequenced. One subject showed heterozygous C2866-->G (Phe21-->Leu) polymorphism. DNA from 157 Chinese subjects (104 polychlorinated biphenyl-exposed subjects and 53 control subjects) was screened for polymorphism by single-strand conformation polymorphism method and MboII endonuclease digestion. Only 1 of 157 samples showed another heterozygous C2866-->G mutation. The subject was previously exposed to polychlorinated biphenyl and showed a value of 3.5% in the caffeine breath test. The value is not significantly higher than the mean value of polychlorinated biphenyl-exposed subjects (3.12 +/- 0.29%, mean +/- S.E.M.). The incidence of the point mutation in these Chinese subjects is less than 1%. The prevalence of the F21L mutation in other ethnic groups and its effect on the metabolic activity of CYP1A2 remain to be further evaluated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9884316

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  8 in total

1.  The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women.

Authors:  Anna Nordmark; Stefan Lundgren; Birgitta Ask; Fredrik Granath; Anders Rane
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

2.  Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population.

Authors:  D S Ou-Yang; S L Huang; W Wang; H G Xie; Z H Xu; Y Shu; H H Zhou
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

3.  Caffeine N3-demethylation (CYP1A2) in a population with an increased exposure to polychlorinated biphenyls.

Authors:  Maria Skaalum Petersen; Jónrit Halling; Per Damkier; Flemming Nielsen; Philippe Grandjean; Pál Weihe; Kim Brøsen
Journal:  Eur J Clin Pharmacol       Date:  2006-11-07       Impact factor: 2.953

Review 4.  Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2.

Authors:  Shu-Feng Zhou; Li-Ping Yang; Zhi-Wei Zhou; Ya-He Liu; Eli Chan
Journal:  AAPS J       Date:  2009-07-10       Impact factor: 4.009

5.  Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism.

Authors:  Christoph Sachse; Upinder Bhambra; Gillian Smith; Tracy J Lightfoot; Jennifer H Barrett; Jenna Scollay; R Colin Garner; Alan R Boobis; C Roland Wolf; Nigel J Gooderham
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

6.  The cytotoxic effect of 2-acylated-1,4-naphthohydroquinones on leukemia/lymphoma cells.

Authors:  Diego A Pedroza; Fernando De Leon; Armando Varela-Ramirez; Carolina Lema; Renato J Aguilera; Shizue Mito
Journal:  Bioorg Med Chem       Date:  2013-12-11       Impact factor: 3.641

Review 7.  Pharmacogenetics: the therapeutic drug monitoring of the future?

Authors:  M H Ensom; T K Chang; P Patel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

8.  PCB exposure and in vivo CYP1A2 activity among Native Americans.

Authors:  Edward F Fitzgerald; Syni-An Hwang; George Lambert; Marta Gomez; Alice Tarbell
Journal:  Environ Health Perspect       Date:  2005-03       Impact factor: 9.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.